Cargando…

Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints

The COVID-19 pandemic continues to have an unprecedented impact on people’s lives and the economy worldwide. Vaccines are the strongest evidence-based defense against the spread of the disease. The release of COVID-19 vaccines to the general public created policy challenges associated with how to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Sengul Orgut, Irem, Freeman, Nickolas, Lewis, Dwight, Parton, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199497/
https://www.ncbi.nlm.nih.gov/pubmed/37275337
http://dx.doi.org/10.1016/j.omega.2023.102898
_version_ 1785044946438324224
author Sengul Orgut, Irem
Freeman, Nickolas
Lewis, Dwight
Parton, Jason
author_facet Sengul Orgut, Irem
Freeman, Nickolas
Lewis, Dwight
Parton, Jason
author_sort Sengul Orgut, Irem
collection PubMed
description The COVID-19 pandemic continues to have an unprecedented impact on people’s lives and the economy worldwide. Vaccines are the strongest evidence-based defense against the spread of the disease. The release of COVID-19 vaccines to the general public created policy challenges associated with how to best allocate vaccines among different sub-regions. In the United States, after vaccines became widely available for all eligible adults, policymakers faced objectives such as ([Formula: see text]) achieving an equitable allocation to reduce populations’ travel times to get vaccinated and ([Formula: see text]) effectively allocating vaccine doses to minimize waste and unmet need. This problem was further exacerbated by the underlying factors of population vaccine hesitancy and sub-regions’ varying capacity levels to administer vaccines to eligible and willing populations. Although simple to implement, commonly used pro rata policies do not capture the complexities of this problem. We propose two alternatives to simple pro rata policies. The first alternative is based on a Mixed-Integer Linear Programming Model that minimizes the maximum travel duration of patients and aims to achieve an equitable and effective allocation of vaccines to sub-regions while considering capacity and vaccine hesitancy. A second alternative is a heuristic approach that may be more palatable for policymakers who ([Formula: see text]) are not familiar with mathematical modeling, ([Formula: see text]) are reluctant to use black-box models, and ([Formula: see text]) prefer algorithms that are easy to understand and implement. We demonstrate the results of our model through a case study based on real data from the state of Alabama and show that substantial improvements in travel time-based equity are achievable through capacity improvements in a small subset of counties. We perform additional computational experiments that compare the proposed methods in terms of several metrics and demonstrate the promising performance of our model and proposed heuristic. We find that while our mathematical model can achieve equitable and effective vaccine allocation, the proposed heuristic performs better if the goal is to minimize average travel duration. Finally, we explore two model extensions that aim to ([Formula: see text]) lower vaccine hesitancy by allocating vaccines, and ([Formula: see text]) prioritize vaccine access for certain high-risk sub-populations.
format Online
Article
Text
id pubmed-10199497
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101994972023-05-22 Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints Sengul Orgut, Irem Freeman, Nickolas Lewis, Dwight Parton, Jason Omega Article The COVID-19 pandemic continues to have an unprecedented impact on people’s lives and the economy worldwide. Vaccines are the strongest evidence-based defense against the spread of the disease. The release of COVID-19 vaccines to the general public created policy challenges associated with how to best allocate vaccines among different sub-regions. In the United States, after vaccines became widely available for all eligible adults, policymakers faced objectives such as ([Formula: see text]) achieving an equitable allocation to reduce populations’ travel times to get vaccinated and ([Formula: see text]) effectively allocating vaccine doses to minimize waste and unmet need. This problem was further exacerbated by the underlying factors of population vaccine hesitancy and sub-regions’ varying capacity levels to administer vaccines to eligible and willing populations. Although simple to implement, commonly used pro rata policies do not capture the complexities of this problem. We propose two alternatives to simple pro rata policies. The first alternative is based on a Mixed-Integer Linear Programming Model that minimizes the maximum travel duration of patients and aims to achieve an equitable and effective allocation of vaccines to sub-regions while considering capacity and vaccine hesitancy. A second alternative is a heuristic approach that may be more palatable for policymakers who ([Formula: see text]) are not familiar with mathematical modeling, ([Formula: see text]) are reluctant to use black-box models, and ([Formula: see text]) prefer algorithms that are easy to understand and implement. We demonstrate the results of our model through a case study based on real data from the state of Alabama and show that substantial improvements in travel time-based equity are achievable through capacity improvements in a small subset of counties. We perform additional computational experiments that compare the proposed methods in terms of several metrics and demonstrate the promising performance of our model and proposed heuristic. We find that while our mathematical model can achieve equitable and effective vaccine allocation, the proposed heuristic performs better if the goal is to minimize average travel duration. Finally, we explore two model extensions that aim to ([Formula: see text]) lower vaccine hesitancy by allocating vaccines, and ([Formula: see text]) prioritize vaccine access for certain high-risk sub-populations. Elsevier Ltd. 2023-10 2023-05-20 /pmc/articles/PMC10199497/ /pubmed/37275337 http://dx.doi.org/10.1016/j.omega.2023.102898 Text en © 2023 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sengul Orgut, Irem
Freeman, Nickolas
Lewis, Dwight
Parton, Jason
Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints
title Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints
title_full Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints
title_fullStr Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints
title_full_unstemmed Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints
title_short Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints
title_sort equitable and effective vaccine access considering vaccine hesitancy and capacity constraints
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199497/
https://www.ncbi.nlm.nih.gov/pubmed/37275337
http://dx.doi.org/10.1016/j.omega.2023.102898
work_keys_str_mv AT sengulorgutirem equitableandeffectivevaccineaccessconsideringvaccinehesitancyandcapacityconstraints
AT freemannickolas equitableandeffectivevaccineaccessconsideringvaccinehesitancyandcapacityconstraints
AT lewisdwight equitableandeffectivevaccineaccessconsideringvaccinehesitancyandcapacityconstraints
AT partonjason equitableandeffectivevaccineaccessconsideringvaccinehesitancyandcapacityconstraints